Events2Join
Ventus Therapeutics Initiates Clinical Testing of VENT|03

Ventus Therapeutics Initiates Clinical Testing of VENT|03

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor ... WALTHAM, Mass. ... “cGAS has ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

UPDATE: Ventus Therapeutics Announces Positive Phase 1 Trial ...

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a phase 2 study for ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial ... initiating a Phase 2 trial with VENT-03 in SLE in 2025." In the ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

WALTHAM, Mass. & MONTREAL, January 03, 2024--Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ...

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

... VENT-01) – an oral NLRP3 inhibitor licensed by Novo ... “This trial initiation marks the first stage in our NLRP3 inhibitor clinical ...

Ventus doses first participant in Phase I clinical trial of VENT-03

Ventus Therapeutics has dosed the first subject in a Phase I clinical trial ... initiation of this Phase I clinical trial. “We are eager to ...

Ventus Begins Phase 1 Trial for VENT-03 cGAS Inhibitor

Ventus Therapeutics, a biopharmaceutical firm at the forefront of clinical-stage research, has initiated a Phase 1 clinical trial for ...

Dosing begins in Phase 1 trial of VENT-03, potential cGAS inhibitor

A first person has been dosed in a Phase 1 clinical trial of VENT-03, Ventus Therapeutics' oral treatment candidate for lupus and other inflammatory diseases.

Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS ...

This marks a significant milestone as VENT-03 is the pioneer cGAS inhibitor to progress into the realm of clinical trials. Please click on the ...

Latest News - Ventus Therapeutics

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor · January 2, 2024. Ventus Therapeutics to ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a ... - Gale

ENPNewswire-January 4, 2024--Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally administered cGAS Inhibitor.

VENT-03, a First-in-Class cGAS Inhibitor - Ventus Therapeutics

... clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability ...

Hung Trinh on LinkedIn: Ventus Therapeutics Announces ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03 ... initiating a Phase 2 trial with VENT-03 in SLE ...

VENT-03 / Ventus Therap - LARVOL DELTA

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor (Businesswire) ...

Ventus Therapeutics - FirstWord Pharma

Press Release · Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

Initiation of clinical trials in CNS diseases expected beginning in the second half of 2024 ... In this Phase 1 clinical trial, VENT-02 was well- ...

Marcelo Bigal, MD, PhD: VENT-03's Modality Offers Hope for ...

Ventus Therapeutics recently initiated a phase 1 clinical trial for VENT-03, the first cGAS inhibitor to advance into clinical development.

More Than Lupus on X: "TUESDAY NEWSDAY! Ventus ...

TUESDAY NEWSDAY! Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...

Ventus Therapeutics on LinkedIn: #ventustx #cgas #vent_03 ...

Today, we announced the initiation of a Phase 1 trial of VENT-03, which marks the first time a cGAS inhibitor has entered the clinic.